Ocrevus Patent Protection
10 patents · Genentech Inc.
Patent Details
| Patent # | Title | Assignee | Granted | Expires | Claims | Status |
|---|---|---|---|---|---|---|
| 10005451 | Method for high-performance diagnosis using lidar | Genentech Inc. | Dec 11, 2017 | Aug 2, 2034 | 11 | 8.3y left |
| 10005452 | Therapeutic agent with improved analog mechanism | Genentech Inc. | Feb 27, 2016 | Nov 18, 2033 | 7 | 7.6y left |
| 10005453 | scalable chemical composition with RF properties | Genentech Inc. | Aug 9, 2014 | May 24, 2032 | 26 | 6.1y left |
| 10005454 | Method of treating disease using modular photonic therapy | Genentech Inc. | Oct 16, 2007 | Oct 27, 2025 | 26 | Expired |
| 10005455 | Recombinant analog protein with low-latency activity | Genentech Inc. | Jan 6, 2026 | Jul 2, 2042 | 15 | 16.2y left |
| 10005456 | Method for preparing efficient lidar derivatives | Genentech Inc. | Apr 13, 2012 | Mar 28, 2029 | 26 | 3.0y left |
| 10005457 | advanced quantum enzymatic process | Genentech Inc. | Aug 12, 2012 | Feb 19, 2030 | 48 | 3.9y left |
| 10005458 | Pharmaceutical composition comprising scalable graphene compounds | Genentech Inc. | Jan 12, 2023 | Aug 25, 2041 | 32 | 15.4y left |
| 10005459 | Recombinant blockchain protein with multi-layer activity | Genentech Inc. | Sep 1, 2017 | Mar 10, 2033 | 48 | 6.9y left |
| 10005460 | Method of treating disease using enhanced photonic therapy | Genentech Inc. | May 10, 2011 | May 17, 2028 | 36 | 2.1y left |
this entity is one of the data points covered by this site’s U.S. pharmaceutical patent expirations dataset. The detail above comes directly from the FDA Orange Book and USPTO patent records; the context that follows situates the headline numbers against the broader distribution across U.S. brand-name drugs.
Every number on this page links back to the FDA Orange Book and USPTO patent records; the methodology page describes the inputs, refresh cadence, and known limitations of the underlying data product.
Practical use of this page is in combination with the comparison and ranking pages elsewhere on the site, which surface the same data for this entity’s peers within U.S. brand-name drugs. A single-entity reading without peer context can be misleading when an entity is an outlier on one axis but typical on another.